Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.